Robert J. Desnick, Ph.D., M.D., D.Sc. (Hon) is a human geneticist whose basic and translational research accomplishments include significant discoveries in genomics, pharmacogenetics, gene therapy, personalized medicine, and the treatment of genetic diseases. His translational research has led to the development of enzyme replacement therapy for Fabry disease, Niemann–Pick disease type B, and RNA Interference Therapy for the . He was the co-founder of Amicus Therapeutics, a biopharmaceutical company developing pharmacologic chaperone therapies (Galafold approved 2018), and served as the Chairman of the Scientific Advisory Committees (SAC) of Synageva BioPharma and Pharmaceuticals. The enzyme therapy developed in his laboratory and licensed to Genzyme as Fabrazyme, along with Cerazyme for